<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Respir Res</journal-id><journal-id journal-id-type="iso-abbrev">Respir. Res</journal-id><journal-title-group><journal-title>Respiratory Research</journal-title></journal-title-group><issn pub-type="ppub">1465-9921</issn><issn pub-type="epub">1465-993X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28821260</article-id><article-id pub-id-type="pmc">5563048</article-id><article-id pub-id-type="publisher-id">636</article-id><article-id pub-id-type="doi">10.1186/s12931-017-0636-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Reisner</surname><given-names>Colin</given-names></name><address><email>creisner@pearltherapeutics.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gottschlich</surname><given-names>Gregory</given-names></name><address><email>ggottschlich@nhcr.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fakih</surname><given-names>Faisal</given-names></name><address><email>FFakih@FPCResearch.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Koser</surname><given-names>Andras</given-names></name><address><email>akoser@gmail.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Krainson</surname><given-names>James</given-names></name><address><email>jkrainson@clinicaltrialsfla.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Delacruz</surname><given-names>Luis</given-names></name><address><email>DeLaCruz@greenvillemedresearch.com</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Arora</surname><given-names>Samir</given-names></name><address><email>sarora@aventivresearch.com</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Feldman</surname><given-names>Gregory</given-names></name><address><email>gfeld3232@aol.com</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Pudi</surname><given-names>Krishna</given-names></name><address><email>krishna@ASHAresearch.com</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Siddiqui</surname><given-names>Shahid</given-names></name><address><email>Shahid.Siddiqui@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Orevillo</surname><given-names>Chad</given-names></name><address><email>chad.orevillo@comcast.net</email></address><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Maes</surname><given-names>Andrea</given-names></name><address><email>amaes@pearltherapeutics.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>St. Rose</surname><given-names>Earl</given-names></name><address><email>estrose@pearltherapeutics.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Ubaldo</given-names></name><address><email>Ubaldo.Martin@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>AstraZeneca, Inc., Gaithersburg, MD USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.418152.b</institution-id><institution/><institution>Pearl Therapeutics, Inc., </institution></institution-wrap>280 Headquarters Plaza, East Tower, Morristown, NJ 07960 USA </aff><aff id="Aff3"><label>3</label>New Horizons Clinical Research, Cincinnati, OH USA </aff><aff id="Aff4"><label>4</label>Florida Pulmonary Research Institute, Winter Park, FL USA </aff><aff id="Aff5"><label>5</label>Palmetto Medical Research Associates, Easley, SC USA </aff><aff id="Aff6"><label>6</label>Clinical Trials of Florida, Miami, FL USA </aff><aff id="Aff7"><label>7</label>Greenville Pharmaceutical Research, Greenville, SC USA </aff><aff id="Aff8"><label>8</label>Aventiv Research, Columbus, OH USA </aff><aff id="Aff9"><label>9</label>S. Carolina Pharmaceutical Research, Spartanburg, SC USA </aff><aff id="Aff10"><label>10</label>Upstate Pharmaceutical Research, Greenville, SC USA </aff><aff id="Aff11"><label>11</label>Former employee of Pearl Therapeutics, Inc., Morristown, NJ USA </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>18</volume><elocation-id>157</elocation-id><history><date date-type="received"><day>8</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>3</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Symptoms of chronic obstructive pulmonary disease may vary throughout the day and it is important that therapeutic approaches provide 24-h symptom control. We report the results of two phase IIIb crossover studies, PT003011 and PT003012, investigating the 24-h lung function profile of GFF MDI (glycopyrrolate/formoterol fumarate 18/9.6 &#x003bc;g delivered using innovative co-suspension delivery technology) administered twice daily.</p></sec><sec><title>Methods</title><p id="Par2">Patients with moderate-to-very severe chronic obstructive pulmonary disease received 4 weeks&#x02019; treatment with each of GFF MDI, placebo MDI, and open-label tiotropium (PT003011 only). Lung function was assessed over 24 h on day 29 of each treatment period. The primary outcome was forced expiratory volume in 1 second area under the curve from 0 to 24 h (FEV<sub>1</sub>AUC<sub>0&#x02013;24</sub>). Other outcomes included change from baseline in average daily rescue medication use over the treatment period. In addition, we conducted a post-hoc analysis of data pooled from both studies to further characterize the effect of GFF MDI on inspiratory capacity.</p></sec><sec><title>Results</title><p id="Par3">GFF MDI treatment significantly increased FEV<sub>1</sub>AUC<sub>0&#x02013;24</sub> versus placebo in studies PT003011 (<italic>n</italic> = 75) and PT003012 (<italic>n</italic> = 35) on day 29 (both studies <italic>p</italic> &#x0003c; 0.0001), with similar improvements in FEV<sub>1</sub>AUC versus placebo for hours 0&#x02013;12 and 12&#x02013;24. In PT003011, improvements with GFF MDI versus tiotropium in FEV<sub>1</sub>AUC were greater during hours 12&#x02013;24 compared to 0&#x02013;12 h. GFF MDI treatment also resulted in a significant reduction in rescue medication use versus placebo (&#x02212;0.84 [<italic>p</italic>&#x0003c;0.0001] and &#x02212;1.11 [<italic>p</italic>=0.0054] puffs/day in PT003011 and PT003012, respectively), and versus tiotropium in PT003011 (&#x02212;0.44 [<italic>p</italic>=0.017] puffs/day). A post-hoc pooled analysis showed patients treated with GFF MDI were more likely to achieve a &#x0003e;15% increase from baseline in inspiratory capacity than patients treated with placebo or tiotropium (72.1%, 19.0% and 47.0% of patients, respectively after the evening dose on day 29). There were no significant safety/tolerability findings.</p></sec><sec><title>Conclusions</title><p id="Par4">GFF MDI significantly improved 24-h lung function versus placebo in patients with moderate-to-very severe chronic obstructive pulmonary disease, with similar benefits in the second 12-h period compared to the first, supporting twice-daily dosing of GFF MDI.</p></sec><sec><title>Trial registration</title><p id="Par5">Pearl Therapeutics, Inc.; <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>; <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02347072">NCT02347072</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02347085">NCT02347085</ext-link>. Registered 21 January 2015.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COPD</kwd><kwd>Muscarinic antagonists</kwd><kwd>&#x003b2;<sub>2</sub>-agonist</kwd><kwd>Co-suspension delivery technology</kwd><kwd>Metered dose inhaler</kwd><kwd>Smoking</kwd><kwd>Chronic bronchitis</kwd><kwd>Emphysema</kwd><kwd>Bronchodilator</kwd></kwd-group><funding-group><award-group><funding-source><institution>This study was funded by Pearl Therapeutics, Inc., a member of the AstraZeneca Group.</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par28">Long-acting bronchodilators have become a key treatment choice for the management of chronic obstructive pulmonary disease (COPD) [<xref ref-type="bibr" rid="CR1">1</xref>]. High-quality evidence from multiple clinical trials suggests that combination treatment with a long-acting muscarinic antagonist (LAMA) and a long-acting &#x003b2;<sub>2</sub>-agonist (LABA) reduces symptoms compared to LAMA or LABA monotherapy [<xref ref-type="bibr" rid="CR2">2</xref>]. COPD symptoms tend to vary throughout the day [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>], and despite treatment, many patients with COPD experience symptoms throughout the whole 24-h day, including night-time and early morning symptoms [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Patients who experience symptoms during any part of the 24-h day have significantly worse outcomes across patient-reported measures (including health status, sleep quality, anxiety, and depression) compared with asymptomatic patients [<xref ref-type="bibr" rid="CR7">7</xref>], highlighting the need for therapeutic approaches that provide 24-h symptom control.</p><p id="Par29">GFF MDI is a twice daily (BID) LAMA/LABA fixed-dose combination (FDC) of glycopyrrolate/formoterol fumarate 18/9.6&#x000a0;&#x003bc;g (equivalent to glycopyrronium/formoterol fumarate dihydrate 14.4/10&#x000a0;&#x003bc;g) delivered by metered dose inhaler (MDI) using innovative co-suspension delivery technology. The co-suspension delivery technology provides a strong, non-specific association between drug crystals and porous particles, allowing uniform dose delivery [<xref ref-type="bibr" rid="CR8">8</xref>]. The efficacy of GFF MDI in improving lung function over 24&#x000a0;weeks versus its monocomponent MDIs was previously evaluated in two pivotal phase III clinical studies (PINNACLE-1 [NCT01854645] and PINNACLE-2 [NCT01854658]) [<xref ref-type="bibr" rid="CR9">9</xref>], which led to approval of GFF MDI (Bevespi Aerosphere&#x02122;) for the long-term, maintenance treatment of airflow obstruction in patients with COPD in the USA [<xref ref-type="bibr" rid="CR10">10</xref>]. A 28-week safety extension of these studies (PINNACLE-3 [NCT01970878]), comparing GFF MDI to its monocomponent MDIs and open-label tiotropium, provided further evidence of a favorable benefit-risk profile [<xref ref-type="bibr" rid="CR11">11</xref>]<italic>.</italic>
</p><p id="Par30">Here, we present the results from two phase IIIb studies, PT003011 (NCT02347072) and PT003012 (NCT02347085), characterizing the 24-h lung-function profile of GFF MDI BID relative to placebo MDI BID in patients with moderate-to-very severe COPD. PT003011 also included open-label tiotropium 5&#x000a0;&#x003bc;g (Spiriva&#x000ae; Respimat&#x000ae;), administered once daily (QD) using a Soft Mist&#x02122; Inhaler (SMI) as an active comparator. In addition, we performed a post-hoc analysis of data pooled from both studies to further evaluate the effect of GFF MDI on inspiratory capacity.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and treatment</title><p id="Par31">PT003011 and PT003012 were crossover, multicenter, randomized, double-blind studies conducted in the USA. The studies had similar designs, with the exception of the inclusion of an open-label tiotropium SMI arm in PT003011. In study PT003011, patients were randomly assigned to one of six treatment sequences, each comprising three 4-week periods of treatment with the following in a crossover fashion: GFF MDI 18/9.6&#x000a0;&#x003bc;g BID; placebo MDI BID; and open-label tiotropium SMI 5&#x000a0;&#x003bc;g QD. In study PT003012, patients were randomly assigned to one of two treatment sequences, comprising two 4-week periods with GFF MDI and placebo MDI treatment administered in a crossover fashion.</p><p id="Par32">Patients were required to discontinue any previous COPD medications during both studies, and were provided with Atrovent&#x000ae; HFA (ipratropium bromide inhalation aerosol, four times daily) and rescue Ventolin&#x000ae; HFA (albuterol sulfate inhalation aerosol, up to four times daily as required) to control symptoms. Use of albuterol sulfate was permitted during the treatment and washout periods as rescue medication. However, ipratropium bromide was only for use during the washout periods and was replaced with study drug during treatment periods. Patients previously using an inhaled corticosteroid as part of an FDC were switched to an equivalent inhaled corticosteroid monotherapy with fluticasone, mometasone, or budesonide.</p><p id="Par33">These studies were conducted in accordance with Good Clinical Practice guidelines including the International Council on Harmonisation, the US Code of Federal Regulations, and the Declaration of Helsinki. All patients provided written informed consent prior to the performance of any screening evaluations.</p></sec><sec id="Sec4"><title>Patients</title><p id="Par34">Patients eligible for inclusion in PT003011 and PT003012 were 40 to 80&#x000a0;years&#x000a0;of age; had moderate-to-very severe COPD (as defined by the American Thoracic Society/European Respiratory Society criteria) [<xref ref-type="bibr" rid="CR12">12</xref>]; and were current or ex-smokers with a history of &#x02265;10 pack-years. Patients who had been hospitalized due to COPD in the past 3&#x000a0;months, had poorly controlled COPD, had changed their smoking status during screening, or required long-term oxygen therapy for &#x0003e;12&#x000a0;h per day were excluded. Both studies allowed patients to withdraw at any point, and investigators could request withdrawal of a patient if they met any of the pre-specified discontinuation criteria.</p></sec><sec id="Sec5"><title>Objectives and endpoints</title><p id="Par35">The objective of these studies was to determine the 24-h efficacy profile of GFF MDI relative to placebo MDI in patients with moderate-to-very severe COPD following chronic dosing (over a 4-week period), with the additional objective of characterizing this profile relative to open-label tiotropium SMI in PT003011.</p><p id="Par36">The primary efficacy outcome for both studies was forced expiratory volume in 1&#x000a0;s (FEV<sub>1</sub>) area under the curve from 0 to 24&#x000a0;h (AUC<sub>0&#x02013;24</sub>) on day 29. The 24-h efficacy profile of GFF MDI was further characterized using secondary efficacy outcomes, including FEV<sub>1</sub> AUC<sub>12&#x02013;24</sub> and FEV<sub>1</sub> AUC<sub>0&#x02013;12</sub> on day 29; peak change from baseline in FEV<sub>1</sub> following evening and morning doses on day 29; change from baseline in morning pre-dose trough FEV<sub>1</sub> on days 29 and 30; and peak change from baseline in inspiratory capacity following evening and morning doses on day 29. Other endpoints included change from baseline in average daily rescue medication use over the treatment period.</p></sec><sec id="Sec6"><title>Assessments</title><p id="Par37">Study visits were scheduled on day 1 and day 29 of each treatment period. On day 29, spirometry was assessed 60 and 30&#x000a0;min prior to drug administration; 15 and 30&#x000a0;min post-dose; and at 1, 2, 4, 8, 11.5, 12, 12.25, 12.5, 13, 14, 16, 22, 23.5, and 24&#x000a0;h post-dosing. Investigators assessed continued eligibility for study participation at each visit. Safety data, including adverse events (AEs), vital sign measurements, electrocardiograms, and clinical laboratory testing, were collected throughout the study.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par38">Assuming a patient dropout rate of 20%, a sample size of 80 randomized patients was estimated to provide 99% power to detect a difference of 200&#x000a0;mL in the primary endpoint for GFF MDI versus placebo MDI with a two-sided alpha level of 0.05; and also to provide 90% power to demonstrate a difference of 75&#x000a0;mL in the primary endpoint between GFF MDI and open-label tiotropium SMI in PT003011. For PT003012, the number of patients necessary to detect a difference of 200&#x000a0;mL in the primary endpoint for GFF MDI versus placebo MDI with a two-sided alpha level of 0.05 was 40.</p><p id="Par39">The primary analyses were conducted using the modified intent-to-treat population (mITT), the subset of the intent-to-treat population that included all patients who received treatment and provided post-treatment efficacy data from at least two treatment periods. The primary endpoint was analyzed using a mixed model, with baseline FEV<sub>1</sub> as a continuous covariate, and period and treatment as unordered categorical covariates. Subject was included as a random effect to model correlation within subject across the study. Secondary endpoints based on FEV<sub>1</sub>, inspiratory capacity, or rescue medication use were analyzed using the same model, with the only difference being that the baseline value was specific to the endpoint.</p><sec id="Sec8"><title>Post-hoc analysis of pooled data</title><p id="Par40">The effect of GFF MDI on inspiratory capacity was further evaluated in a post-hoc analysis of pooled data from both studies (mITT population). Inspiratory capacity responder analyses, using various thresholds, were conducted using a logistic regression model with covariates for study, baseline inspiratory capacity, treatments nested within study, and period nested within study. Point estimates with 95% confidence intervals were produced for each treatment difference, with no adjustments made for multiplicity.</p></sec></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Patients</title><p id="Par41">In study PT003011, 80 patients were randomized to one of six treatment sequences; whilst in PT003012, 43 patients were randomized to one of two treatment sequences (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Overall, 75 patients were included in the mITT population in PT003011 and 35 patients in PT003012. Patient demographics were generally similar across both studies and treatment groups (Table <xref rid="Tab1" ref-type="table">1</xref>). The higher proportion of female patients in study PT003011 compared to PT003012 (64.0% vs 42.9%) was not considered to be clinically relevant. Current smoking status and duration of COPD were similar across groups in both of the studies.<fig id="Fig1"><label>Fig. 1</label><caption><p>Patient disposition. GFF, glycopyrrolate/formoterol fumarate; MDI, metered dose inhaler; SMI, Soft Mist&#x02122; inhaler; TIO, open-label tiotropium</p></caption><graphic xlink:href="12931_2017_636_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient demographics and baseline characteristics (mITT population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">PT003011</th><th colspan="2">PT003012</th></tr><tr><th>GFF MDI<break/>18/9.6&#x000a0;&#x003bc;g<break/>(<italic>n</italic>&#x000a0;=&#x000a0;73)</th><th>Placebo<break/>MDI<break/>(<italic>n</italic>&#x000a0;=&#x000a0;69)</th><th>TIO SMI<break/>5&#x000a0;&#x003bc;g<break/>(<italic>n</italic>&#x000a0;=&#x000a0;73)</th><th>GFF MDI<break/>18/9.6&#x000a0;&#x003bc;g<break/>(<italic>n</italic>&#x000a0;=&#x000a0;35)</th><th>Placebo<break/>MDI<break/>(<italic>n</italic>&#x000a0;=&#x000a0;35)</th></tr></thead><tbody><tr><td>Mean age, years (SD)</td><td>61.9 (9.1)</td><td>61.7 (9.1)</td><td>61.9 (8.9)</td><td>61.3 (9.2)</td><td>61.3 (9.2)</td></tr><tr><td>Male, <italic>n</italic> (%)</td><td>26 (35.6)</td><td>24 (34.8)</td><td>27 (37.0)</td><td>20 (57.1)</td><td>20 (57.1)</td></tr><tr><td>White, <italic>n</italic> (%)</td><td>66 (90.4)</td><td>63 (91.3)</td><td>66 (90.4)</td><td>27 (77.1)</td><td>27 (77.1)</td></tr><tr><td>Current smokers, <italic>n</italic> (%)</td><td>45 (61.6)</td><td>43 (62.3)</td><td>45 (61.6)</td><td>20 (57.1)</td><td>20 (57.1)</td></tr><tr><td>Mean smoking history, pack-years (SD)</td><td>56.4 (29.2)</td><td>57.6 (29.3)</td><td>55.9 (29.3)</td><td>49.0 (25.2)</td><td>49.0 (25.2)</td></tr><tr><td>Use of ICS at baseline, <italic>n</italic> (%)</td><td>23 (31.5)</td><td>20 (29.0)</td><td>22 (30.1)</td><td>10 (28.6)</td><td>10 (28.6)</td></tr><tr><td colspan="6">COPD severity, <italic>n</italic> (%)</td></tr><tr><td>&#x02003;Moderate</td><td>53 (72.6)</td><td>47 (68.1)</td><td>51 (69.9)</td><td>20 (57.1)</td><td>20 (57.1)</td></tr><tr><td>&#x02003;Severe</td><td>20 (27.4)</td><td>22 (31.9)</td><td>22 (30.1)</td><td>14 (40.0)</td><td>14 (40.0)</td></tr><tr><td>&#x02003;Very severe</td><td>0</td><td>0</td><td>0</td><td>1 (2.9)</td><td>1 (2.9)</td></tr><tr><td>Mean COPD duration, years (SD)</td><td>6.8 (5.9)</td><td>7.2 (6.1)</td><td>7.1 (6.0)</td><td>6.3 (4.7)</td><td>6.3 (4.7)</td></tr><tr><td colspan="6">Mean pre-bronchodilator FEV<sub>1</sub>
</td></tr><tr><td>&#x02003;mL (SD)</td><td>1410 (461)</td><td>1396 (466)</td><td>1414 (460)</td><td>1406 (542)</td><td>1406 (542)</td></tr><tr><td>&#x02003;% predicted (SD)</td><td>52.54 (13.97)</td><td>51.70 (14.20)</td><td>52.33 (14.11)</td><td>48.34 (16.20)</td><td>48.34 (16.20)</td></tr><tr><td colspan="6">Mean post-bronchodilator FEV<sub>1</sub>
</td></tr><tr><td>&#x02003;mL (SD)</td><td>1542 (435)</td><td>1521 (434)</td><td>1546 (434)</td><td>1525 (538)</td><td>1525 (538)</td></tr><tr><td>&#x02003;% predicted (SD)</td><td>57.69 (13.50)</td><td>56.61 (13.61)</td><td>57.44 (13.68)</td><td>52.51 (15.35)</td><td>52.51 (15.35)</td></tr><tr><td>Baseline IC<sup>a</sup>, mL (SD)</td><td>1877 (527)</td><td>1913 (560)</td><td>1925 (546)</td><td>1979 (656)</td><td>1942 (632)</td></tr><tr><td>Average daily rescue medication use at baseline<sup>b</sup>, puffs/day (SD)</td><td>2.5 (3.5)</td><td>2.6 (3.7)</td><td>2.6 (3.6)</td><td>3.4 (3.4)</td><td>3.4 (3.4)</td></tr><tr><td>Patients with a moderate or severe COPD exacerbation<sup>c</sup> within the past 12 months<sup>d</sup>, <italic>n</italic> (%)</td><td>13 (17.3)</td><td>12 (16.7)</td><td>12 (16.4)</td><td>10 (25.0)</td><td>10 (25.0)</td></tr><tr><td>Patients hospitalized/ER room treatment within the past 12 months<sup>d</sup>, <italic>n</italic> (%)</td><td>4 (5.3)</td><td>5 (6.9)</td><td>5 (6.8)</td><td>0</td><td>0</td></tr></tbody></table><table-wrap-foot><p>
<italic>COPD</italic> chronic obstructive pulmonary disease, <italic>FEV</italic>
<sub><italic>1</italic></sub> forced expiratory volume in 1&#x000a0;s, <italic>GFF</italic> glycopyrrolate/formoterol fumarate, <italic>IC</italic> inspiratory capacity, <italic>ICS</italic> inhaled corticosteroids, <italic>MDI</italic> metered dose inhaler, <italic>mITT</italic> modified intent-to-treat, <italic>SD</italic> standard deviation, <italic>SMI</italic> Soft Mist&#x02122; inhaler, <italic>TIO</italic> open-label tiotropium</p><p>
<sup>a</sup>Baseline IC was defined as the mean of the pre-dose values on the first day of each treatment period, where the mean of the 30- and 60-min values for each visit day was obtained, and then the visit means were averaged</p><p>
<sup>b</sup>Baseline rescue medication use was defined as the average daily number of puffs used over the 7&#x000a0;days prior to the date of first dose in Treatment Period 1</p><p>
<sup>c</sup>A COPD exacerbation was defined as a change in the subject&#x02019;s baseline dyspnea, cough, and/or sputum (increase in volume or change in color towards purulence) that lasted &#x02265;3&#x000a0;days, was beyond normal day to day variations, was acute in onset, and may have warranted a change in regular medication</p><p>
<sup>d</sup>Safety population. PT003011: GFF MDI, <italic>n</italic>&#x000a0;=&#x000a0;75; Placebo MDI, <italic>n</italic>&#x000a0;=&#x000a0;72; TIO SMI, <italic>n</italic>&#x000a0;=&#x000a0;73. PT003012: GFF MDI, <italic>n</italic>&#x000a0;=&#x000a0;40; Placebo MDI, <italic>n</italic>&#x000a0;=&#x000a0;40</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Efficacy</title><p id="Par42">In both studies, treatment with GFF MDI led to significant improvements in the primary efficacy endpoint, change from baseline in FEV<sub>1</sub> AUC<sub>0&#x02013;24</sub> on day 29. GFF MDI treatment resulted in improvements of 265&#x000a0;mL and 249&#x000a0;mL (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 for both) for FEV<sub>1</sub> AUC<sub>0&#x02013;24</sub> relative to placebo MDI treatment (PT003011 and PT003012, respectively; Fig. <xref rid="Fig2" ref-type="fig">2</xref>). In study PT003011, GFF MDI also led to an 80&#x000a0;mL improvement relative to open-label tiotropium SMI (<italic>p</italic>&#x000a0;=&#x000a0;0.0001). An increase of FEV<sub>1</sub> AUC relative to open-label tiotropium SMI was seen over both the 0&#x02013;12&#x000a0;h and 12&#x02013;24&#x000a0;h intervals. However, the magnitude of this increase was greater over the 12&#x02013;24-h period. Differences between GFF MDI and open-label tiotropium SMI groups in change from baseline in FEV<sub>1</sub> AUC were 48&#x000a0;mL (<italic>p</italic>&#x000a0;=&#x000a0;0.0325) and 120&#x000a0;mL (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001), respectively, for 0&#x02013;12&#x000a0;h and 12&#x02013;24&#x000a0;h. For GFF MDI versus placebo MDI, the improvement was similar across both time periods in both studies (Table <xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Adjusted change from baseline in FEV<sub>1</sub> over 24&#x000a0;h on day 29. Data shown are &#x000b1; SE for the mITT population in (<bold>a</bold>) PT003011 and (<bold>b</bold>) PT003012. AUC, area under the curve; FEV<sub>1</sub>, forced expiratory volume in 1&#x000a0;s; GFF, glycopyrrolate/formoterol fumarate; LSM, least squares means; MDI, metered dose inhaler; mITT, modified intent-to-treat; SE, standard error; SMI, Soft Mist&#x02122; inhaler</p></caption><graphic xlink:href="12931_2017_636_Fig2_HTML" id="MO2"/></fig>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Secondary endpoints: lung-function measurements (mITT population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">PT003011</th><th colspan="2">PT003012</th></tr><tr><th>GFF MDI<break/>18/9.6&#x000a0;&#x003bc;g</th><th>Placebo<break/>MDI</th><th>TIO SMI<break/>5&#x000a0;&#x003bc;g</th><th>GFF MDI<break/>18/9.6&#x000a0;&#x003bc;g</th><th>Placebo<break/>MDI</th></tr></thead><tbody><tr><td/><td>
<italic>n</italic>&#x000a0;=&#x000a0;65</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;65</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;67</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;35</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;31</td></tr><tr><td>FEV<sub>1</sub> AUC<sub>12&#x02013;24</sub>&#x000a0;(mL) on day 29, LSM (SE)</td><td>159 (27.7)</td><td>&#x02212;118 (27.7)</td><td>39 (27.5)</td><td>115 (29.9)</td><td>&#x02212;127 (32.0)</td></tr><tr><td>&#x02003;
<italic>Treatment difference GFF MDI</italic> vs <italic>comparator LSM (95% CI)</italic>
</td><td>NA</td><td>277 (232&#x02013;321)</td><td>120 (76&#x02013;164)</td><td>NA</td><td>242 (165&#x02013;319)</td></tr><tr><td/><td>
<italic>n</italic>&#x000a0;=&#x000a0;67</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;66</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;68</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;35</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;31</td></tr><tr><td>FEV<sub>1</sub> AUC<sub>0&#x02013;12</sub>&#x000a0;(mL) on day 29, LSM (SE)</td><td>226 (25.7)</td><td>&#x02212;26 (25.8)</td><td>178 (25.6)</td><td>216 (29.8)</td><td>&#x02212;39 (31.8)</td></tr><tr><td>&#x02003;
<italic>Treatment difference GFF MDI</italic> vs <italic>comparator LSM (95% CI)</italic>
</td><td>NA</td><td>251 (207&#x02013;296)</td><td>48 (4&#x02013;92)</td><td>NA</td><td>255 (182&#x02013;329)</td></tr><tr><td/><td>
<italic>n</italic>&#x000a0;=&#x000a0;65</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;65</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;67</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;35</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;31</td></tr><tr><td>Peak change from baseline in FEV<sub>1</sub> (mL) following evening dose on day 29, LSM (SE)</td><td>395 (30.9)</td><td>58 (31)</td><td>230 (30.7)</td><td>344 (34.2)</td><td>50 (36.6)</td></tr><tr><td>&#x02003;
<italic>Treatment difference GFF MDI</italic> vs <italic>comparator LSM (95% CI)</italic>
</td><td>NA</td><td>337 (282&#x02013;392)</td><td>165 (110&#x02013;219)</td><td>NA</td><td>293 (204&#x02013;382)</td></tr><tr><td/><td>
<italic>n</italic>&#x000a0;=&#x000a0;67</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;67</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;68</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;35</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;31</td></tr><tr><td>Peak change from baseline in FEV<sub>1</sub> (mL) following morning dose on day 29, LSM (SE)</td><td>406 (28.3)</td><td>129 (28.3)</td><td>325 (28.1)</td><td>410 (35.8)</td><td>134 (37.6)</td></tr><tr><td>&#x02003;
<italic>Treatment difference GFF MDI</italic> vs <italic>comparator LSM (95% CI)</italic>
</td><td>NA</td><td>278 (225&#x02013;330)</td><td>81 (29&#x02013;133)</td><td>NA</td><td>276 (206&#x02013;347)</td></tr><tr><td/><td>
<italic>n</italic>&#x000a0;=&#x000a0;67</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;66</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;68</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;35</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;32</td></tr><tr><td>Change from baseline in morning pre-dose trough FEV<sub>1</sub> on day 29 (mL), LSM (SE)</td><td>140 (22.7)</td><td>&#x02212;20 (22.9)</td><td>97 (22.5)</td><td>130 (21.7)</td><td>&#x02212;12 (22.7)</td></tr><tr><td>&#x02003;
<italic>Treatment difference GFF MDI</italic> vs <italic>comparator LSM (95% CI)</italic>
</td><td>NA</td><td>161 (106&#x02013;215)</td><td>43 (&#x02212;11&#x02013;97)</td><td>NA</td><td>142 (90&#x02013;194)</td></tr><tr><td/><td>
<italic>n</italic>&#x000a0;=&#x000a0;66</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;66</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;66</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;35</td><td>
<italic>n</italic>&#x000a0;=&#x000a0;31</td></tr><tr><td>Change from baseline in morning pre-dose trough FEV<sub>1</sub> on day 30 (mL), LSM (SE)</td><td>129 (28.4)</td><td>&#x02212;73 (28.4)</td><td>72 (28.3)</td><td>90 (28.8)</td><td>&#x02212;64 (30.2)</td></tr><tr><td>&#x02003;
<italic>Treatment difference GFF MDI</italic> vs <italic>comparator LSM (95% CI)</italic>
</td><td>NA</td><td>203 (153&#x02013;252)</td><td>58 (8&#x02013;108)</td><td>NA</td><td>154 (97&#x02013;211)</td></tr></tbody></table><table-wrap-foot><p>
<italic>AUC</italic> area under the curve, <italic>CI</italic> confidence interval, <italic>FEV</italic>
<sub><italic>1</italic></sub> forced expiratory volume in 1&#x000a0;s, <italic>GFF</italic> glycopyrrolate/formoterol fumarate, <italic>LSM</italic> least squares means, <italic>MDI</italic> metered dose inhaler; <italic>mITT</italic>, modified intent-to-treat, <italic>NA</italic> not applicable, <italic>SE</italic> standard error, <italic>SMI</italic> Soft Mist&#x02122; inhaler, <italic>TIO</italic> open-label tiotropium</p></table-wrap-foot></table-wrap>
</p><p id="Par43">In both studies, treatment with GFF MDI resulted in a significant difference in peak change from baseline in FEV<sub>1</sub> versus placebo MDI, with numerically greater differences in the evening compared to in the morning (Table <xref rid="Tab2" ref-type="table">2</xref>). Additionally, in PT003011, treatment with GFF MDI led to significant improvements in peak change from baseline in FEV<sub>1</sub> versus tiotropium (81&#x000a0;mL in the morning and 165&#x000a0;mL in the evening of day 29, <italic>p</italic>&#x000a0;&#x02264;&#x000a0;0.0026).</p><p id="Par44">GFF MDI treatment improved morning pre-dose trough FEV<sub>1</sub> versus placebo MDI in both studies, and versus open-label tiotropium SMI in PT003011. For all parameters, improvements were greater on day 30 than on day 29 (Table <xref rid="Tab2" ref-type="table">2</xref>). Improvements in peak change from baseline in inspiratory capacity with GFF MDI compared to placebo MDI or open-label tiotropium SMI followed a similar trend as peak change from baseline in FEV<sub>1</sub> and were greater following the evening dose compared to the morning dose (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). After both doses, differences between the GFF MDI and open-label tiotropium SMI groups on day 29 were significant, with a 124&#x000a0;mL (<italic>p</italic>&#x000a0;=&#x000a0;0.0035) difference between the two treatment groups in the evening, and an 80&#x000a0;mL (<italic>p</italic>&#x000a0;=&#x000a0;0.0287) difference in the morning (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Peak change from baseline in IC on day 29 (evening/morning). Data shown are &#x000b1; SE for the mITT population in (<bold>a</bold>) PT003011 and (<bold>b</bold>) PT003012. GFF, glycopyrrolate/formoterol fumarate; IC, inspiratory capacity; LSM, least squares means; MDI, metered dose inhaler; mITT, modified intent-to-treat; SE, standard error; SMI, Soft Mist&#x02122; inhaler</p></caption><graphic xlink:href="12931_2017_636_Fig3_HTML" id="MO3"/></fig>
</p><p id="Par45">As well as resulting in significant improvements in spirometry measurements, patients treated with GFF MDI used significantly less rescue medication (&#x02212;0.84 [<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001] and &#x02212;1.11 [<italic>p</italic>&#x000a0;=&#x000a0;0.0054] puffs/day in PT003011 and PT003012, respectively) than those treated with placebo MDI (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). For GFF MDI versus open-label tiotropium SMI, rescue medication use was reduced by 0.44 puffs/day (<italic>p</italic>&#x000a0;=&#x000a0;0.017).<fig id="Fig4"><label>Fig. 4</label><caption><p>Change from baseline in average daily rescue medication use over 4-week treatment period. Data shown are &#x000b1; SE for mITT population in (<bold>a</bold>) PT003011 and (<bold>b</bold>) PT003012. GFF, glycopyrrolate/formoterol fumarate; LSM, least squares means; MDI, metered dose inhaler; mITT, modified intent-to-treat; SE, standard error; SMI, Soft Mist&#x02122; inhaler</p></caption><graphic xlink:href="12931_2017_636_Fig4_HTML" id="MO4"/></fig>
</p><sec id="Sec12"><title>Post-hoc analysis of pooled data</title><p id="Par46">In a post-hoc analysis of pooled data from both studies, 72.1% of patients treated with GFF MDI achieved a&#x000a0;&#x0003e;15% increase from baseline in inspiratory capacity on day 29 in the evening, compared to 19.0% of patients treated with placebo MDI and 47.0% of patients treated with open-label tiotropium SMI (Table <xref rid="Tab3" ref-type="table">3</xref>). Inspiratory capacity responder analyses with thresholds of &#x0003e;10%, &#x0003e;20%, &#x0003e;200&#x000a0;mL, &#x0003e;300&#x000a0;mL, and &#x0003e;400&#x000a0;mL on day 29 demonstrated that consistently higher proportions of patients treated with GFF MDI achieved a response compared to patients treated with placebo MDI or open-label tiotropium SMI in both the morning and evening assessments (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Pooled analysis of IC response on day 29 (mITT population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">Response in peak IC</th><th colspan="3">Treatment versus comparator, OR (95% CI)</th></tr><tr><th>GFF MDI<break/>18/9.6&#x000a0;&#x003bc;g<break/>
<italic>n</italic>&#x000a0;=&#x000a0;102</th><th>Placebo<break/>MDI<break/>
<italic>n</italic>&#x000a0;=&#x000a0;99</th><th>TIO SMI<break/>5&#x000a0;&#x003bc;g<break/>
<italic>n</italic>&#x000a0;=&#x000a0;68</th><th>GFF MDI vs placebo MDI</th><th>GFF MDI vs TIO SMI</th><th>TIO SMI vs placebo MDI</th></tr></thead><tbody><tr><td colspan="7">Patients achieving a response (evening), %</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;10%</td><td>83.5</td><td>31.5</td><td>71.1</td><td>11.00 (4.12&#x02013;29.43)</td><td>2.05 (0.83&#x02013;5.10)</td><td>5.36 (2.13&#x02013;13.49)</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;15%</td><td>72.1</td><td>19.0</td><td>47.0</td><td>10.98 (4.34&#x02013;27.79)</td><td>2.91 (1.27&#x02013;6.68)</td><td>3.77 (1.58&#x02013;8.98)</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;20%</td><td>54.8</td><td>15.3</td><td>31.4</td><td>6.70 (2.98&#x02013;15.08)</td><td>2.65 (1.27&#x02013;5.51)</td><td>2.53 (1.12&#x02013;5.74)</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;200&#x000a0;mL</td><td>83.1</td><td>27.8</td><td>61.3</td><td>12.78 (4.70&#x02013;34.79)</td><td>3.12 (1.25&#x02013;7.79)</td><td>4.10 (1.68&#x02013;9.99)</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;300&#x000a0;mL</td><td>66.3</td><td>20.0</td><td>43.4</td><td>7.84 (3.47&#x02013;17.74)</td><td>2.56 (1.22&#x02013;5.37)</td><td>3.06 (1.38&#x02013;6.79)</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;400&#x000a0;mL</td><td>46.5</td><td>10.3</td><td>20.9</td><td>7.58 (3.09&#x02013;18.63)</td><td>3.29 (1.42&#x02013;7.61)</td><td>2.31 (0.89&#x02013;5.96)</td></tr><tr><td colspan="7">Patients achieving a response (morning), %</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;10%</td><td>92.1</td><td>47.2</td><td>75.2</td><td>12.94 (4.57&#x02013;36.68)</td><td>3.82 (1.38&#x02013;10.57)</td><td>3.39 (1.39&#x02013;8.30)</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;15%</td><td>81.4</td><td>30.1</td><td>65.5</td><td>10.16 (4.11&#x02013;25.14)</td><td>2.31 (0.98&#x02013;5.46)</td><td>4.39 (1.85&#x02013;10.44)</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;20%</td><td>75.6</td><td>12.5</td><td>46.8</td><td>21.72 (6.58&#x02013;71.65)</td><td>3.53 (1.32&#x02013;9.47)</td><td>6.15 (2.06&#x02013;18.35)</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;200&#x000a0;mL</td><td>89.5</td><td>40.7</td><td>72.8</td><td>12.37 (4.82&#x02013;31.78)</td><td>3.17 (1.27&#x02013;7.94)</td><td>3.90 (1.70&#x02013;8.95)</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;300&#x000a0;mL</td><td>79.1</td><td>23.6</td><td>67.4</td><td>12.24 (4.62&#x02013;32.47)</td><td>1.83 (0.75&#x02013;4.45)</td><td>6.69 (2.51&#x02013;17.80)</td></tr><tr><td>&#x02003;&#x000a0;&#x0003e;&#x000a0;400&#x000a0;mL</td><td>67.9</td><td>13.3</td><td>34.0</td><td>13.84 (5.24&#x02013;36.54)</td><td>4.12 (1.77&#x02013;9.60)</td><td>3.36 (1.33&#x02013;8.51)</td></tr></tbody></table><table-wrap-foot><p>
<italic>CI</italic> confidence interval, <italic>GFF</italic> glycopyrrolate/formoterol fumarate, <italic>IC</italic> inspiratory capacity, <italic>MDI</italic> metered dose inhaler, <italic>mITT</italic> modified intent-to-treat, <italic>OR</italic> odds ratio, <italic>SMI</italic> Soft Mist&#x02122; inhaler, <italic>TIO</italic> open-label tiotropium</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec13"><title>Safety and tolerability</title><p id="Par47">GFF MDI was generally well tolerated in both studies, although in PT003011 there was a higher incidence of treatment-emergent AEs in the GFF MDI treatment group. The most common AEs are summarized in Table <xref rid="Tab4" ref-type="table">4</xref>. Serious AEs occurred at a similar rate in the GFF MDI treatment groups as in the placebo MDI groups. In PT003011, one serious AE of COPD in the GFF MDI group was considered related to study drug by the investigator. No deaths occurred during either of these studies.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Summary of adverse events<sup>a</sup> (safety population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">PT003011</th><th colspan="2">PT003012</th></tr><tr><th>GFF MDI<break/>18/9.6&#x000a0;&#x003bc;g<break/>(<italic>n</italic>&#x000a0;=&#x000a0;75)</th><th>Placebo<break/>MDI<break/>(<italic>n</italic>&#x000a0;=&#x000a0;72)</th><th>TIO SMI<break/>5&#x000a0;&#x003bc;g<break/>(<italic>n</italic>&#x000a0;=&#x000a0;73)</th><th>GFF MDI<break/>18/9.6&#x000a0;&#x003bc;g<break/>(<italic>n</italic>&#x000a0;=&#x000a0;40)</th><th>Placebo<break/>MDI<break/>(<italic>n</italic>&#x000a0;=&#x000a0;40)</th></tr></thead><tbody><tr><td>Patients with &#x02265;1 TEAE</td><td>19 (25.3)</td><td>15 (20.8)</td><td>16 (21.9)</td><td>7 (17.5)</td><td>10 (25.0)</td></tr><tr><td>Patients with &#x02265;1 treatment-related TEAE</td><td>7 (9.3)</td><td>4 (5.6)</td><td>3 (4.1)</td><td>0</td><td>1 (2.5)</td></tr><tr><td>Patients with &#x02265;1 serious TEAE</td><td>2 (2.7)</td><td>2 (2.8)</td><td>2 (2.7)</td><td>1 (2.5)</td><td>1 (2.5)</td></tr><tr><td>Patients with TEAEs leading to study discontinuation</td><td>3 (4.0)</td><td>1 (1.4)</td><td>1 (1.4)</td><td>1 (2.5)</td><td>1 (2.5)</td></tr><tr><td colspan="6">Adverse events occurring in &#x02265;2 patients in any group</td></tr><tr><td>Respiratory, thoracic, and mediastinal disorders</td><td>2 (2.7)</td><td>4 (5.6)</td><td>3 (4.1)</td><td>0</td><td>5 (12.5)</td></tr><tr><td>&#x02003;Dyspnea</td><td>0</td><td>0</td><td>1 (1.4)</td><td>0</td><td>2 (5.0)</td></tr><tr><td>&#x02003;Sinus congestion</td><td>0</td><td>0</td><td>0</td><td>0</td><td>2 (5.0)</td></tr><tr><td>&#x02003;Cough</td><td>1 (1.3)</td><td>2 (2.8)</td><td>1 (1.4)</td><td>0</td><td>1 (2.5)</td></tr><tr><td>Infections and infestations</td><td>6 (8.0)</td><td>2 (2.8)</td><td>4 (5.5)</td><td>3 (7.5)</td><td>2 (5.0)</td></tr><tr><td>&#x02003;Furuncle</td><td>0</td><td>0</td><td>2 (2.7)</td><td>0</td><td>0</td></tr><tr><td>Vascular disorders</td><td>0</td><td>0</td><td>0</td><td>1 (2.5)</td><td>3 (7.5)</td></tr><tr><td>&#x02003;Hypertension</td><td>0</td><td>0</td><td>0</td><td>1 (2.5)</td><td>2 (5.0)</td></tr><tr><td>Gastrointestinal disorders</td><td>5 (6.7)</td><td>4 (5.6)</td><td>5 (6.8)</td><td>0</td><td>0</td></tr><tr><td>&#x02003;Constipation</td><td>2 (2.7)</td><td>1 (1.4)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>&#x02003;Vomiting</td><td>0</td><td>0</td><td>3 (4.1)</td><td>0</td><td>0</td></tr><tr><td>Nervous system disorders</td><td>4 (5.3)</td><td>2 (2.8)</td><td>2 (2.7)</td><td>0</td><td>0</td></tr><tr><td>&#x02003;Headache</td><td>1 (1.3)</td><td>2 (2.8)</td><td>1 (1.4)</td><td>0</td><td>0</td></tr><tr><td>&#x02003;Tremor</td><td>3 (4.0)</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Musculoskeletal and connective tissue disorders</td><td>2 (2.7)</td><td>2 (2.8)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>&#x02003;Back pain</td><td>1 (1.3)</td><td>2 (2.8)</td><td>0</td><td>0</td><td>0</td></tr></tbody></table><table-wrap-foot><p>
<italic>GFF</italic> glycopyrrolate/formoterol fumarate, <italic>MDI</italic> metered dose inhaler, <italic>SMI</italic> Soft Mist&#x02122; inhaler, <italic>TEAE</italic> treatment-emergent adverse event, <italic>TIO</italic> open-label tiotropium</p><p>
<sup>a</sup>Data shown are number of patients (%)</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec14"><title>Discussion</title><p id="Par48">In these two phase IIIb studies (PT003011 and PT003012), the LAMA/LABA FDC GFF MDI 18/9.6&#x000a0;&#x003bc;g BID formulated using innovative co-suspension delivery technology improved lung-function parameters in patients with moderate-to-very severe COPD over 24&#x000a0;h. GFF MDI is the first available LAMA/LABA FDC maintenance treatment for COPD patients to be delivered using a MDI. The use of a MDI could be particularly beneficial in patients with hyperinflation and reduced inspiratory capacity, who may find it difficult to achieve the minimum inspiratory flow required for a dry powder inhaler [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par49">The results of PT003011 and PT003012 are in agreement with the PINNACLE-1 and -2 studies, which showed significant improvements in lung-function measures such as morning pre-dose trough FEV<sub>1</sub> over 24&#x000a0;weeks of treatment with GFF MDI, compared with placebo MDI [<xref ref-type="bibr" rid="CR9">9</xref>]. Together with the PINNACLE-3 study [<xref ref-type="bibr" rid="CR11">11</xref>], the data presented here provide additional evidence for both long- and short-term efficacy and safety of GFF MDI as a maintenance treatment for moderate-to-very severe COPD.</p><p id="Par50">In previous studies assessing 24-h lung-function profiles of LAMA/LABA combinations, patients treated with tiotropium/olodaterol (QD via a SMI) or umeclidinium/vilanterol (QD via a dry powder inhaler) also showed significant improvements in lung function over a 24-h period compared with patients receiving placebo or monocomponents [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. However, unlike in our study with a BID dosing regimen, in these QD dosing studies improvements were lower in the 12&#x02013;24-h period than in the 0&#x02013;12-h period [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Few studies have assessed the 24-h lung-function profile of a bronchodilator with a BID dosing regimen [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par51">A previous study investigating the effect of adding formoterol QD or BID to tiotropium QD treatment found that the addition of formoterol BID led to significant improvements in FEV<sub>1</sub> over 12&#x02013;24&#x000a0;h compared to tiotropium alone [<xref ref-type="bibr" rid="CR18">18</xref>]. In another study comparing formoterol BID to olodaterol QD, the evening dose of formoterol led to an increase in night-time FEV<sub>1</sub> compared to placebo and olodaterol [<xref ref-type="bibr" rid="CR19">19</xref>], suggesting that BID dosing of a LABA can also provide overnight lung-function benefits in patients with COPD. In both PT003011 and PT003012, patients treated with GFF MDI BID showed significantly greater changes from baseline in spirometry measures over the whole 24-h period compared with patients receiving placebo MDI or open-label tiotropium SMI QD. These improvements were most noticeable during the 12&#x02013;24-h period of the study, suggesting that GFF MDI BID treatment could provide prolonged lung-function benefits in the second half of the day (including overnight) compared to once-daily LAMA and possibly LAMA/LABA treatment.</p><p id="Par52">Circadian variations in FEV<sub>1</sub> have been reported in patients with COPD, with peak values observed during daytime hours and a decrease in FEV<sub>1</sub> occurring overnight [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. In a study investigating the effect of the timing of tiotropium dosing on overnight FEV<sub>1</sub>, administration of tiotropium in the evening did not significantly improve overnight FEV<sub>1</sub> in comparison to dosing in the morning [<xref ref-type="bibr" rid="CR21">21</xref>]. In the present study, the administration of GFF MDI BID did improve overnight FEV<sub>1</sub> in comparison to placebo MDI BID and open-label tiotropium SMI QD (Table <xref rid="Tab2" ref-type="table">2</xref>; Fig. <xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par53">GFF MDI BID also provided significant improvements in inspiratory capacity, which were sustained over a 24-h period. An additional post-hoc analysis of data pooled from PT003011 and PT003012 found that patients receiving GFF MDI BID were more likely to achieve an inspiratory capacity response than those treated with placebo MDI BID and open-label tiotropium SMI QD, which was consistent over a range of response thresholds and for both the morning and evening assessments.</p><p id="Par54">It has been demonstrated previously that low inspiratory capacity is correlated with decreased exercise tolerance [<xref ref-type="bibr" rid="CR22">22</xref>] and increased dyspnea in patients with COPD [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>], although one study found that dyspnea was more closely linked to improvements in FEV<sub>1</sub> than inspiratory capacity [<xref ref-type="bibr" rid="CR26">26</xref>]. In addition, inspiratory capacity has been shown to be a predictor of all-cause and respiratory mortality in patients with COPD; and is linked to hospitalizations due to COPD exacerbations [<xref ref-type="bibr" rid="CR27">27</xref>]. Hence, improving inspiratory capacity may improve exercise capacity and dyspnea symptoms, and have an impact on long-term disease outcomes.</p><p id="Par55">A potential limitation of this study was the open-label nature of the tiotropium arm, whereas GFF MDI and placebo MDI were supplied blinded. However, this was in part mitigated by dosing patients in the clinic for the 24-h assessment at the end of each treatment period. A strength of this study was the crossover design, which provided equivalent power to a much larger parallel study. This allowed for within-subject comparison of active treatment versus placebo, which provides a better correction for diurnal variation than a parallel study design.</p></sec><sec id="Sec15"><title>Conclusions</title><p id="Par56">These studies showed that, in patients with moderate-to-very severe COPD, the twice-daily LAMA/LABA treatment GFF MDI resulted in a reduction in airflow limitation and hyperinflation, demonstrated by significant benefits on inspiratory capacity in comparison to placebo MDI and once-daily open-label tiotropium SMI. These effects were sustained over the whole 24-h period. The studies also evidenced a similar safety and tolerability profile for GFF MDI, placebo MDI, and open-label tiotropium SMI. Benefits compared to once-daily tiotropium SMI were greater in the 12&#x02013;24-h period, suggesting that GFF MDI twice-daily treatment could offer longer-lasting improvements in night-time lung function over once-daily dosing regimens.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AE</term><def><p id="Par6">Adverse event</p></def></def-item><def-item><term>AUC<sub>x-xx</sub></term><def><p id="Par7">Area under the curve from X to XX hours</p></def></def-item><def-item><term>BID</term><def><p id="Par8">Twice daily</p></def></def-item><def-item><term>CI</term><def><p id="Par9">Confidence interval</p></def></def-item><def-item><term>COPD</term><def><p id="Par10">Chronic obstructive pulmonary disease</p></def></def-item><def-item><term>FDC</term><def><p id="Par11">Fixed-dose combination</p></def></def-item><def-item><term>FEV<sub>1</sub></term><def><p id="Par12">Forced expiratory volume in 1&#x000a0;s</p></def></def-item><def-item><term>GFF</term><def><p id="Par13">Glycopyrrolate/formoterol fumarate</p></def></def-item><def-item><term>IC</term><def><p id="Par14">Inspiratory capacity</p></def></def-item><def-item><term>ICS</term><def><p id="Par15">Inhaled corticosteroids</p></def></def-item><def-item><term>LABA</term><def><p id="Par16">Long-acting &#x003b2;<sub>2</sub>-agonist</p></def></def-item><def-item><term>LAMA</term><def><p id="Par17">Long-acting muscarinic antagonist</p></def></def-item><def-item><term>LSM</term><def><p id="Par18">Least squares mean</p></def></def-item><def-item><term>MDI</term><def><p id="Par19">Metered dose inhaler</p></def></def-item><def-item><term>mITT</term><def><p id="Par20">modified intent-to-treat</p></def></def-item><def-item><term>NA</term><def><p id="Par21">Not applicable</p></def></def-item><def-item><term>QD</term><def><p id="Par22">Once daily</p></def></def-item><def-item><term>SD</term><def><p id="Par23">Standard deviation</p></def></def-item><def-item><term>SE</term><def><p id="Par24">Standard error</p></def></def-item><def-item><term>SMI</term><def><p id="Par25">Soft Mist&#x02122; Inhaler</p></def></def-item><def-item><term>TEAE</term><def><p id="Par26">Treatment-emergent adverse event</p></def></def-item><def-item><term>TIO</term><def><p id="Par27">Open-label tiotropium</p></def></def-item></def-list></glossary><ack><p>The authors would like to thank all of the patients and their families, the team of investigators, research nurses, and operations staff involved in these studies.</p><p>The authors also thank Carol McNair, PhD of Complete Medical Communications, Macclesfield, UK for providing medical writing support which was funded by AstraZeneca, Cambridge, UK in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464).</p><sec id="FPar1"><title>Funding</title><p id="Par57">Pearl Therapeutics, Inc., a member of the AstraZeneca Group.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par58">The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>CR, GC, FF, AK, JK, LD, SA, GF, KP, SS, CO, AM, ESR and UM made substantial contributions to the conception or design of the studies reported. GG, FF, AK, JK, LD, SA, GF and KP participated in the acquisition of reported data. CR, SS, CO, AM, ESR and UM participated in the analysis of reported data. CR, GC, FF, AK, JK, LD, SA, GF, KP, SS, CO, AM, ESR and UM participated in the interpretation of reported data. All authors contributed to the writing of the manuscript and participated in the review and interpretation of the data. All authors read and approved the final manuscript before submission.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par59">These studies were conducted in accordance with Good Clinical Practice guidelines including the International Council on Harmonisation, the US Code of Federal Regulations, and the Declaration of Helsinki. All patients provided written informed consent prior to the performance of any screening evaluations.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par60">Not applicable</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par61">CR and SS are employees of AstraZeneca.</p><p id="Par62">AK was the Principal Investigator at Palmetto Medical Research Associates, LLC for this clinical research trial, and was paid a fee for his activities as an investigator. He is also a part owner of this research site.</p><p id="Par63">JK reports personal fees from AstraZeneca, outside of the submitted work.</p><p id="Par64">CO is a former employee of Pearl Therapeutics, Inc., and reports receiving personal fees from Pearl Therapeutics, Inc. outside of the submitted work.</p><p id="Par65">AM and ESR are employees of Pearl Therapeutics, Inc.</p><p id="Par66">UM is an employee of and holds shares in AstraZeneca.</p><p id="Par67">GG, FF, LD, SA, GF, and KP have no potential competing interests to disclose.</p><p id="Par68">Bevespi Aerosphere&#x02122; is a trademark of the AstraZeneca group of companies.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par69">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barjaktarevic</surname><given-names>IZ</given-names></name><name><surname>Arredondo</surname><given-names>AF</given-names></name><name><surname>Cooper</surname><given-names>CB</given-names></name></person-group><article-title>Positioning new pharmacotherapies for COPD</article-title><source>Int J Chron Obstruct Pulmon Dis.</source><year>2015</year><volume>10</volume><fpage>1427</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.2147/COPD.S83758</pub-id><pub-id pub-id-type="pmid">26244017</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, GOLD. 2017. <ext-link ext-link-type="uri" xlink:href="http://www.goldcopd.org">http://www.goldcopd.org</ext-link>. Accessed 7 Apr 2017.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Partridge</surname><given-names>MR</given-names></name><name><surname>Karlsson</surname><given-names>N</given-names></name><name><surname>Small</surname><given-names>IR</given-names></name></person-group><article-title>Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey</article-title><source>Curr Med Res Opin</source><year>2009</year><volume>25</volume><fpage>2043</fpage><lpage>2048</lpage><pub-id pub-id-type="doi">10.1185/03007990903103006</pub-id><pub-id pub-id-type="pmid">19569976</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>R</given-names></name><name><surname>Partridge</surname><given-names>MR</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Vogelmeier</surname><given-names>C</given-names></name><name><surname>Leynaud</surname><given-names>D</given-names></name><etal/></person-group><article-title>Symptom variability in patients with severe COPD: a pan-European cross-sectional study</article-title><source>Eur Respir J</source><year>2011</year><volume>37</volume><fpage>264</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1183/09031936.00051110</pub-id><pub-id pub-id-type="pmid">21115606</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephenson</surname><given-names>JJ</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Mocarski</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Doshi</surname><given-names>JA</given-names></name><name><surname>Sullivan</surname><given-names>SD</given-names></name></person-group><article-title>Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2015</year><volume>10</volume><fpage>577</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.2147/COPD.S76157</pub-id><pub-id pub-id-type="pmid">25844033</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>B</given-names></name><name><surname>DiBonavaentura</surname><given-names>M</given-names></name><name><surname>Karlsson</surname><given-names>N</given-names></name><name><surname>Bergstrom</surname><given-names>G</given-names></name><name><surname>Holmgren</surname><given-names>U</given-names></name></person-group><article-title>A cross-sectional assessment of the burden of chronic obstructive pulmonary disease (COPD) symptoms in the United States and Europe using the National Health and Wellness Survey</article-title><source>Am J Respir Crit Care Med</source><year>2016</year><volume>193</volume><fpage>A6156</fpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Worth</surname><given-names>H</given-names></name><name><surname>Soler Catalu&#x000f1;a</surname><given-names>JJ</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>De Benedetto</surname><given-names>F</given-names></name><name><surname>Roche</surname><given-names>N</given-names></name><etal/></person-group><article-title>Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study</article-title><source>Respir Res</source><year>2014</year><volume>15</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.1186/s12931-014-0122-1</pub-id><pub-id pub-id-type="pmid">25331383</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vehring</surname><given-names>R</given-names></name><name><surname>Lechuga-Ballesteros</surname><given-names>D</given-names></name><name><surname>Joshi</surname><given-names>V</given-names></name><name><surname>Noga</surname><given-names>B</given-names></name><name><surname>Dwivedi</surname><given-names>SK</given-names></name></person-group><article-title>Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers</article-title><source>Langmuir</source><year>2012</year><volume>28</volume><fpage>15015</fpage><lpage>15023</lpage><pub-id pub-id-type="doi">10.1021/la302281n</pub-id><pub-id pub-id-type="pmid">22985189</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>FJ</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name><name><surname>Fabbri</surname><given-names>LM</given-names></name><name><surname>Rennard</surname><given-names>S</given-names></name><name><surname>Feldman</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD</article-title><source>Chest</source><year>2017</year><volume>151</volume><fpage>340</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2016.11.028</pub-id><pub-id pub-id-type="pmid">27916620</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">AstraZeneca Pharmaceuticals LP. Bevespi Aerosphere prescribing information. 2016. <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208294s000lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208294s000lbl.pdf</ext-link>. Accessed 27 May 2017.</mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanania</surname><given-names>NA</given-names></name><name><surname>Tashkin</surname><given-names>DP</given-names></name><name><surname>Kerwin</surname><given-names>EM</given-names></name><name><surname>Donohue</surname><given-names>JF</given-names></name><name><surname>Denenberg</surname><given-names>M</given-names></name><name><surname>O'Donnell</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Long term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel co-suspension&#x02122; delivery technology in patients with chronic obstructive pulmonary disease</article-title><source>Respir Med</source><year>2017</year><volume>26</volume><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2017.03.015</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>BR</given-names></name><name><surname>MacNee</surname><given-names>W</given-names></name></person-group><article-title>Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper</article-title><source>Eur Respir J</source><year>2004</year><volume>23</volume><fpage>932</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1183/09031936.04.00014304</pub-id><pub-id pub-id-type="pmid">15219010</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Showair</surname><given-names>RA</given-names></name><name><surname>Tarsin</surname><given-names>WY</given-names></name><name><surname>Assi</surname><given-names>KH</given-names></name><name><surname>Pearson</surname><given-names>SB</given-names></name><name><surname>Chrystyn</surname><given-names>H</given-names></name></person-group><article-title>Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?</article-title><source>Respir Med</source><year>2007</year><volume>101</volume><fpage>2395</fpage><lpage>2401</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2007.06.008</pub-id><pub-id pub-id-type="pmid">17629471</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>CH</given-names></name><name><surname>Lovings</surname><given-names>TM</given-names></name><name><surname>Ohar</surname><given-names>JA</given-names></name></person-group><article-title>Low inspiratory flow rates predict COPD and all cause readmissions</article-title><source>Am J Respir Crit Care Med</source><year>2016</year><volume>193</volume><fpage>A1125</fpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Westerman</surname><given-names>J</given-names></name><name><surname>Kirsten</surname><given-names>AM</given-names></name><name><surname>H&#x000e9;bert</surname><given-names>J</given-names></name><name><surname>Gr&#x000f6;nke</surname><given-names>L</given-names></name><name><surname>Hamilton</surname><given-names>A</given-names></name><etal/></person-group><article-title>The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease</article-title><source>Pulm Pharmacol Ther</source><year>2015</year><volume>32</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.pupt.2015.04.002</pub-id><pub-id pub-id-type="pmid">25956072</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donohue</surname><given-names>JF</given-names></name><name><surname>Maleki-Yazdi</surname><given-names>MR</given-names></name><name><surname>Kilbride</surname><given-names>S</given-names></name><name><surname>Mehta</surname><given-names>R</given-names></name><name><surname>Kalberg</surname><given-names>C</given-names></name><name><surname>Church</surname><given-names>A</given-names></name></person-group><article-title>Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD</article-title><source>Respir Med</source><year>2013</year><volume>107</volume><fpage>1538</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2013.06.001</pub-id><pub-id pub-id-type="pmid">23830094</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beier</surname><given-names>J</given-names></name><name><surname>Kirsten</surname><given-names>AM</given-names></name><name><surname>Mr&#x000f3;z</surname><given-names>R</given-names></name><name><surname>Segarra</surname><given-names>R</given-names></name><name><surname>Chuecos</surname><given-names>F</given-names></name><name><surname>Caracta</surname><given-names>C</given-names></name><etal/></person-group><article-title>Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study</article-title><source>COPD</source><year>2013</year><volume>10</volume><fpage>511</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.3109/15412555.2013.814626</pub-id><pub-id pub-id-type="pmid">23819698</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Noord</surname><given-names>JA</given-names></name><name><surname>Aumann</surname><given-names>JL</given-names></name><name><surname>Janssens</surname><given-names>E</given-names></name><name><surname>Verhaert</surname><given-names>J</given-names></name><name><surname>Smeets</surname><given-names>JJ</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD</article-title><source>Chest</source><year>2006</year><volume>129</volume><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1378/chest.129.3.509</pub-id><pub-id pub-id-type="pmid">16537846</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Feldman GJ, Bernstein JA, Hamilton A, Nivens MC, Korducki L, Laforce C. The 24-h FEV1 time profile of olodaterol once daily via Respimat&#x000ae; and formoterol twice daily via Aerolizer&#x000ae; in patients with GOLD 2-4 COPD: results from two 6-week crossover studies. Springerplus. 2014;3:419.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J. 1995;8:1506&#x02013;13.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Towse</surname><given-names>L</given-names></name><name><surname>van Noord</surname><given-names>J</given-names></name><name><surname>Witek</surname><given-names>TJ</given-names></name><name><surname>Kelsen</surname><given-names>S</given-names></name></person-group><article-title>Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>2003</year><volume>58</volume><fpage>855</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1136/thorax.58.10.855</pub-id><pub-id pub-id-type="pmid">14514937</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>O</given-names></name><name><surname>Villafranca</surname><given-names>C</given-names></name><name><surname>Ghezzo</surname><given-names>H</given-names></name><name><surname>Borzone</surname><given-names>G</given-names></name><name><surname>Leiva</surname><given-names>A</given-names></name><name><surname>Milic-Emil</surname><given-names>J</given-names></name><etal/></person-group><article-title>Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest</article-title><source>Eur Respir J</source><year>2000</year><volume>16</volume><fpage>269</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1034/j.1399-3003.2000.16b14.x</pub-id><pub-id pub-id-type="pmid">10968502</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin</surname><given-names>JM</given-names></name><name><surname>Carrizo</surname><given-names>SJ</given-names></name><name><surname>Gascon</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>A</given-names></name><name><surname>Gallego</surname><given-names>B</given-names></name><name><surname>Celli</surname><given-names>BR</given-names></name></person-group><article-title>Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><fpage>1395</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.163.6.2003172</pub-id><pub-id pub-id-type="pmid">11371407</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>DE</given-names></name><name><surname>Lam</surname><given-names>M</given-names></name><name><surname>Webb</surname><given-names>KA</given-names></name></person-group><article-title>Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>160</volume><fpage>542</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.160.2.9901038</pub-id><pub-id pub-id-type="pmid">10430726</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>DE</given-names></name><name><surname>Fluge</surname><given-names>T</given-names></name><name><surname>Gerken</surname><given-names>F</given-names></name><name><surname>Hamilton</surname><given-names>A</given-names></name><name><surname>Webb</surname><given-names>K</given-names></name><name><surname>Aguilaniu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD</article-title><source>Eur Respir J</source><year>2004</year><volume>23</volume><fpage>832</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1183/09031936.04.00116004</pub-id><pub-id pub-id-type="pmid">15218994</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>K</given-names></name><name><surname>Yasui</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Oga</surname><given-names>T</given-names></name></person-group><article-title>Airflow limitation or static hyperinflation: which is more closely related to dyspnea with activities of daily living in patients with COPD?</article-title><source>Respir Res</source><year>2011</year><volume>12</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-12-135</pub-id><pub-id pub-id-type="pmid">21988843</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tantucci</surname><given-names>C</given-names></name><name><surname>Donati</surname><given-names>P</given-names></name><name><surname>Nicosia</surname><given-names>F</given-names></name><name><surname>Bertella</surname><given-names>E</given-names></name><name><surname>Redolfi</surname><given-names>S</given-names></name><name><surname>De Vecchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inspiratory capacity predicts mortality in patients with chronic obstructive pulmonary disease</article-title><source>Respir Med</source><year>2008</year><volume>102</volume><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2007.11.004</pub-id><pub-id pub-id-type="pmid">18083020</pub-id></element-citation></ref></ref-list></back></article>